Fig. 3From: A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinomaComparison of serum AST, ALT, CREA, TBIL, ALB and BUN levels between the two patient groups. A AST, B ALT, C CREA, DTBIL, E ALB and F BUNBack to article page